<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/324129</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;324129</article-id><article-id pub-id-type="other" hwp:sub-type="slug">324129</article-id><article-id pub-id-type="other" hwp:sub-type="tag">324129</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Clinical Trials" hwp:journal="biorxiv"><subject>Clinical Trials</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Dose Escalation for Locally Advanced Pancreatic Cancer: How High Can We Go?</article-title></title-group><author-notes hwp:id="author-notes-1"><fn id="n1" fn-type="conflict" hwp:id="fn-1"><p hwp:id="p-1"><bold>Conflicts of Interest:</bold> None</p></fn><corresp id="cor1" hwp:id="corresp-1"><bold>Corresponding Author:</bold> Cullen M. Taniguchi, MD PhD The University of Texas MD Anderson Cancer Center Division of Radiation Oncology 1515 Holcombe Blvd, Unit 1050 Houston, TX 77030-4000 <email hwp:id="email-1">ctaniguchi@mdanderson.org</email></corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5806-4339</contrib-id><name name-style="western" hwp:sortable="Colbert Lauren E."><surname>Colbert</surname><given-names>Lauren E.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0001-5806-4339"/></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Rebueno Neal"><surname>Rebueno</surname><given-names>Neal</given-names></name><degrees>CMD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Moningi Shalini"><surname>Moningi</surname><given-names>Shalini</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Beddar Sam"><surname>Beddar</surname><given-names>Sam</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Sawakuchi Gabriel"><surname>Sawakuchi</surname><given-names>Gabriel</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-5" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Herman Joseph"><surname>Herman</surname><given-names>Joseph</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-6" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Koong Albert C."><surname>Koong</surname><given-names>Albert C.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-7" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Das Prajnan"><surname>Das</surname><given-names>Prajnan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-8" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Holliday Emma"><surname>Holliday</surname><given-names>Emma</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-9" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-10"><name name-style="western" hwp:sortable="Koay Eugene J."><surname>Koay</surname><given-names>Eugene J.</given-names></name><degrees>MD,PhD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-10" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-11"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8052-3316</contrib-id><name name-style="western" hwp:sortable="Taniguchi Cullen M."><surname>Taniguchi</surname><given-names>Cullen M.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-11" hwp:rel-id="aff-1">1</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-8052-3316"/></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4 xref-aff-1-5 xref-aff-1-6 xref-aff-1-7 xref-aff-1-8 xref-aff-1-9 xref-aff-1-10 xref-aff-1-11"><label>1</label><institution hwp:id="institution-1">Department of Radiation Oncology, University of Texas MD Anderson Cancer Center</institution>, 1515 Holcombe Blvd, Houston TX 77030</aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-05-18T15:14:54-07:00">
    <day>18</day><month>5</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-05-18T15:14:54-07:00">
    <day>18</day><month>5</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-05-18T15:20:19-07:00">
    <day>18</day><month>5</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-05-18T15:20:19-07:00">
    <day>18</day><month>5</month><year>2018</year>
  </pub-date><elocation-id>324129</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-05-16"><day>16</day><month>5</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-05-16"><day>16</day><month>5</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-05-18"><day>18</day><month>5</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-2">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="324129.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/324129v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="324129.xml"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/324129v1/324129v1.htslp"/><kwd-group kwd-group-type="author" hwp:id="kwd-group-1"><title hwp:id="title-1">Key Words</title><kwd hwp:id="kwd-1">SBRT</kwd><kwd hwp:id="kwd-2">Pancreatic Cancer</kwd></kwd-group><counts><page-count count="19"/></counts><custom-meta-wrap>
    <custom-meta hwp:id="custom-meta-1">
      <meta-name>has-earlier-version</meta-name>
      <meta-value>yes</meta-value>
    </custom-meta>
  </custom-meta-wrap></article-meta></front><body><sec id="s1" hwp:id="sec-1"><title hwp:id="title-2">Introduction</title><p hwp:id="p-3">Locally advanced pancreatic cancer (LAPC) is particularly difficult to treat given that it exhibits a poor response to chemotherapy and is by definition unresectable. A large proportion of patients experience significant morbidity and mortality due to local progression. As systemic therapy improves with the advent of gemcitabine/ abraxane<sup><xref rid="c1" ref-type="bibr" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref></sup> and FOLFIRINOX<sup><xref rid="c2" ref-type="bibr" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref></sup>, the burden of local disease will only increase. Standard radiation therapy doses have failed to improve survival, which is not unexpected given anatomical and technical limitations. Although the LAP-07 trial<sup><xref rid="c3" ref-type="bibr" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref></sup> failed to show an overall survival benefit to radiation at standard doses, it did show benefits in terms of local control and time off of chemotherapy. At higher radiation doses, however, our institutional data suggests improved overall survival (17.8 months vs 15 months)<sup><xref rid="c4" ref-type="bibr" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref></sup> and recurrence-free survival (10.2 months vs 6.2 months), in addition to decreased acute grade 3+ gastrointestinal toxicity (1% vs 14%)<sup><xref rid="c5" ref-type="bibr" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref></sup> even at higher doses (BED&gt;70Gy) with advanced radiation delivery techniques including use of 4-dimensional computed tomography, breath-hold technique, and image-guided radiation therapy.</p><p hwp:id="p-4">Given these initial retrospective data, we initiated a phase I/II adaptive dose escalation trial using image guided stereotactic body radiation therapy (SBRT) for LAPC at our institution (ClinicalTrials.gov Identifier: <ext-link l:rel="related" l:ref-type="CLINTRIALGOV" l:ref="NCT03340974" ext-link-type="clintrialgov" xlink:href="NCT03340974" hwp:id="ext-link-2">NCT03340974</ext-link>) to determine the clinical maximum tolerated dose using SBRT. In preparation for the activation of this protocol, we undertook a dosimetric feasibility study to determine a) whether all patients treated with IMRT could have also been planned with SBRT and b) the maximum feasible delivered biological effective dose (BED) using SBRT while maintaining standard organ at risk (OAR) constraints to gastrointestinal (GI) mucosa with daily imaging, motion management, and treatment planning techniques that would be available at most academic centers.</p></sec><sec id="s2" hwp:id="sec-2"><title hwp:id="title-3">Methods</title><sec id="s2a" hwp:id="sec-3"><title hwp:id="title-4">Patient Selection</title><p hwp:id="p-5">The first ten sequential SBRT patients treated at our institution using SBRT at a dose of 40Gy in 5 fractions or 36Gy in 5 fractions (SD-SBRT) were selected for this study. Ten patients originally treated with dose-escalated hypofractionated IMRT (DE-IMRT; 67.5Gy in 15 fractions) were randomly selected from our previously published cohort in order to obtain a fair distribution of patients. All patients received 4 to 6 months of standard induction chemotherapy and on restaging exhibited unresectable disease based on a multidisciplinary review of computed tomography (CT) images using standard criteria<sup><xref rid="c6" ref-type="bibr" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref></sup>. Patients previously treated with DE-IMRT generally had tumors located &gt;5mm from GI mucosa (OAR’s) with no predefined size limit, while SD-SBRT patients had tumors &lt;4cm in maximal dimension with no evidence of duodenal invasion on imaging or endoscopy.</p></sec><sec id="s2b" hwp:id="sec-4"><title hwp:id="title-5">Immobilization and Simulation</title><p hwp:id="p-6">SD-SBRT patients had multiple fiducial markers implanted prior to simulation. DE-IMRT and DE-SBRT patients were immobilized using upper body vac-lock cradles. All patients were simulated NPO for three hours, using intravenous (IV) contrast and inspiration breath hold (IBH) with 5-6 scans for reproducibility. Typically two IBH CT scans were acquired without IV contrast followed by 3-4 IBH CT scans acquired after IV contrast injection performed in intervals of approximately 30 s between scans beginning 30 seconds after IV contrast administration. Simulation technique and example IBH CT scans are described in <xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1</xref>.</p><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1" hwp:rev-id="xref-fig-1-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1.</label><caption hwp:id="caption-1"><title hwp:id="title-6">Serial BH images post contrast</title><p hwp:id="p-7">Using a standard contrast enhanced protocol. Representative image from same axial slice in same patient at: A) 30s post-contrast infusion, B) 60s postcontrast infusion, C) 90s post-contrast infusion, D) 120s postcontrast infusion, and E) 150s post-contrast infusion</p></caption><graphic xlink:href="324129_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig></sec><sec id="s2c" hwp:id="sec-5"><title hwp:id="title-7">Target Delineation and Creation of Simultaneous Integrated Boost (SIB)</title><p hwp:id="p-8">All tumors from DE-IMRT and SD-SBRT patients were re-contoured and validated by two separate physicians (LE and CT) with identical targets using commercial treatment planning software (Phillips Pinnacle version 9.10). The IBH CT images were used to contour an integrated GTV (iGTV) and integrated OAR structures (iDuodenum, iStomach and iSmallBowel; <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2a</xref>). This is a similar concept to a respiratory internal target volume (ITV), created by accounting for physiologic movement of a target. The iOAR structures were uniformly expanded by 5mm expansion to create a GI mucosa planning risk volume (GI_PRV). Example contours are given in <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2</xref>.</p><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2.</label><caption hwp:id="caption-2"><title hwp:id="title-8">Target and OAR contouring technique using BH scans</title></caption><graphic xlink:href="324129_fig2" position="float" orientation="portrait" hwp:id="graphic-2"/></fig><p hwp:id="p-9">For each DE-IMRT and SD-SBRT, we attempted to created a dose-escalated SBRT (DE-SBRT) plan with an SIB to 40 Gy (8Gy/fx) and 70Gy (14Gy/fx) in 5 fractions. The PTV_40 was created by adding 3mm to the iGTV and subtracting the GI_PRV. A PTV_70 was created from the iGTV with 3mm contraction in 3 dimensions. DE-IMRT patients were re-planned for a 40Gy in 5 fractions SBRT plan and a 40Gy in 5 fraction plan with an increased simultaneous integrated boost (SIB) dose until the highest possible dose was reached (up to 70 Gy), while maintaining set OAR constraints (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref>). The ten SD-SBRT patients were re-planned with a DE-IMRT plan and a DE-SBRT plan with an increased SIB. A tumor-vessel interface (TVI) has been included in recent trials to escalate dose to the SMA/ tumor interface. This was not used in our study to simplify plan comparisons, but areas of increased dose were pushed posteriorly to vessel interface rather than anteriorly whenever possible.</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2 xref-table-wrap-1-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1.</label><caption hwp:id="caption-3"><p hwp:id="p-10">Previously Reported Dose Constraints and Associated Toxicities</p></caption><graphic xlink:href="324129_tbl1a" position="float" orientation="portrait" hwp:id="graphic-3"/><graphic xlink:href="324129_tbl1b" position="float" orientation="portrait" hwp:id="graphic-4"/></table-wrap></sec><sec id="s2d" hwp:id="sec-6"><title hwp:id="title-9">Treatment Planning and Evaluatio</title><p hwp:id="p-11">Planning was performed in one of the IV contrast IBH CT scans without density override for the IV contrast. 40Gy was prescribed to the PTV_40 with a SIB technique prescribing 70Gy to the PTV_70. There was no minimum coverage requirement for the iGTV, but &gt;95% coverage was requested for the PTVs. OAR’s were prioritized during IMRT planning over target coverage. Successful plans typically had between 7 and 12 coplanar beam angles. VMAT was acceptable if available for treatment delivery with breathhold. Example treatment plans are presented in <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3</xref>. Based on toxicities observed in previous SBRT trials and the associated constraints (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref>), dose constraints defined for planning purposes (<xref ref-type="table" rid="tbl2" hwp:id="xref-table-wrap-2-1" hwp:rel-id="T2">Table 2</xref>) were: Duodenum V20&lt;20cc, V35&lt;1cc, Dmax&lt;40Gy; Small Bowel V20&lt;20cc, V35&lt;1cc, Dmax&lt;40Gy; Stomach V20&lt;20cc, V35&lt;1cc, Dmax&lt;40Gy.</p><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3.</label><caption hwp:id="caption-4"><title hwp:id="title-10">Sample plans for deSBRT patients</title><p hwp:id="p-12">Each row is a different set of patients. Left column is full axial slice and accompanying right column is zoomed in on areas of interest.</p></caption><graphic xlink:href="324129_fig3" position="float" orientation="portrait" hwp:id="graphic-5"/></fig><table-wrap id="tbl2" orientation="portrait" position="float" hwp:id="T2" hwp:rev-id="xref-table-wrap-2-1 xref-table-wrap-2-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1/TBL2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T2</object-id><object-id pub-id-type="publisher-id">tbl2</object-id><label>Table 2.</label><caption hwp:id="caption-5"><p hwp:id="p-13">Pre-study and post-study Dose Constraints for Dose Escalated SBRT</p></caption><graphic xlink:href="324129_tbl2" position="float" orientation="portrait" hwp:id="graphic-6"/></table-wrap><p hwp:id="p-14">Conformality index was calculated using prescription isodose volume (PIV; 40Gy)/ prescription target volume (PTV) and homogeneity index was calculated using both D95/D5 and Dmax/Dmin formulas. Gradient index was calculated using 50% PIV / 100% PIV.</p></sec><sec id="s2e" hwp:id="sec-7"><title hwp:id="title-11">Statistical Analysis</title><p hwp:id="p-15">Descriptive statistics were generated for all targets and all OAR. The 90<sup>th</sup> percentile was used as a minimum threshold for reasonably achievable OAR contstraints. A minimum coverage percent of 60 percent was defined as acceptable for a dose escalation level.</p></sec><sec id="s2f" hwp:id="sec-8"><title hwp:id="title-12">Treatment Delivery</title><p hwp:id="p-16">All DE-IMRT were treated in a Clinac 2100 EX (Varian Medical Systems, Palo Alto, CA) equipped with a CT on rails (CTOR) (Smart Gantry, GE Healthcare, Chicago, IL). SD-SBRT patients were treated in a Truebeam (Varian Medical System) or the Clinac 2100 EX. For CTOR treatments, patients were initially set up under IBH using radiopaque skin marks placed on the planning final isocenter followed by CTOR under IBH. In-house software (Court and Dong 2003, Med Phys 30:2750) was used to register the CTOR to the planning CT using a contour of the vertebral body located just posterior to the iGTV. The final targets were then manually aligned using the implanted fiducial markers. The auto registration software then provides the couch shifts relative to the radiopaque skin marks to align the patient to the treatment final isocenter. Finally, a MV image pair is acquired to verify the bony alignment and treatment is delivered. For the Truebeam treatments, patients were initially set up to the planning final isocenter then aligned to fiducials using a kilovoltage image pair with cone beam CT (CBCT) for verification. Schema for standard treatment delivery using CTOR is given in <xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 5</xref>.</p></sec></sec><sec id="s3" hwp:id="sec-9"><title hwp:id="title-13">Results</title><p hwp:id="p-17">Clinically acceptable DE-SBRT plans based on iGTV and PTV coverage and OAR constraints were generated for 100% of patients originally treated with DE-IMRT. Acceptable DE-IMRT plans were also generated for 100% of patients originally planned with SD-SBRT. For the maximum dose escalated SBRT plans (<xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Figure 4</xref>), mean PTV volume was 58.8cc (range 8.7-171.91; ±41.3cc). Mean iGTV volume was 40.4cc (range 3.3-119.06; ±31.9). Mean conformality index was 0.98 (±0.24). Mean homogeneity index using Dmax/Dmin was 2.26 (±0.21) and using D95/D5 was 1.77 (±0.05). Mean PTV coverage by the 40Gy line was 97.6% (±0.02%). Mean iGTV coverage by 50Gy was 91% (±0.07%), by 60Gy was 61.3% (±0.08%) and by 70Gy was 24.4% (±0.05%). Maximum PTV coverage by 70Gy was 33%. Maximum PTV coverage by 60Gy was 77.5%. Distributions for conformality and homogeneity and gradient indices and target coverage are given in <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 3</xref>. Distributions for V20, V30 and V35 for all OAR’s are given in <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 3</xref>. The following OAR constraints were achieved for ≥90% of generated plans: Duodenum V20&lt;30cc, V30&lt;3cc, V35&lt;1cc; Small Bowel V20&lt;15cc, V30&lt;1cc, V35&lt;0.1cc; Stomach V20&lt;20cc, V30&lt;2cc, V35&lt;1cc. V40&lt;0.5cc was achieved for all OAR. These post-study dose constraints are listed in <xref ref-type="table" rid="tbl2" hwp:id="xref-table-wrap-2-2" hwp:rel-id="T2">table 2</xref>.</p><fig id="fig4" position="float" orientation="portrait" fig-type="figure" hwp:id="F4" hwp:rev-id="xref-fig-4-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4.</label><caption hwp:id="caption-6"><title hwp:id="title-14">Distribution of OAR constraints and GTV/PTV coverage tradeoff</title></caption><graphic xlink:href="324129_fig4" position="float" orientation="portrait" hwp:id="graphic-7"/></fig><fig id="fig5" position="float" orientation="portrait" fig-type="figure" hwp:id="F5" hwp:rev-id="xref-fig-5-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;324129v1/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Figure 5.</label><caption hwp:id="caption-7"><title hwp:id="title-15">Typical Daily IGRT Process for DE-SRBT</title></caption><graphic xlink:href="324129_fig5" position="float" orientation="portrait" hwp:id="graphic-8"/></fig></sec><sec id="s4" hwp:id="sec-10"><title hwp:id="title-16">Discussion</title><p hwp:id="p-18">Dosimetrically, all patients treated with IMRT could also have been treated with SBRT, with similar (or improved) BED delivery. Given this, it is worth investigating SBRT techniques for patient convenience and continuity of systemic therapy. Based on the 90<sup>th</sup> percentile used in the above data, dose escalation with an SIB technique to 60Gy in 5 fractions is achievable while maintaining acceptable target coverage and standard OAR constraints. We note that our study was enriched in patients with more favorable anatomy (uncinate and body tumors), but we believe that our approach and dose constraints would also apply to any patient that is eligible for pancreatic SBRT.</p><p hwp:id="p-19">Our SIB approach covered the GTV between 60% and 80% by the highest doses while still maintaining &gt;98% PTV coverage by the 40Gy line. Pancreatic tumors are particularly hypoxic at their core<sup><xref rid="c7" ref-type="bibr" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref></sup>, and delivering high doses to this hypoxic core may have a radiobiologic advantage despite not achieving full target coverage. This concept is similar to acceptance of dose heterogeneity within the GTV in other forms of SBRT<sup><xref rid="c8" ref-type="bibr" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref></sup>. Past SBRT trials, even with three and one fraction regimens have shown that duodenum, small bowel and stomach constraints of V20&lt;30cc, V35&lt;1cc, and max dose&lt;40Gy are safe and well tolerated (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-3" hwp:rel-id="T1">Table 1</xref>). Using the above planning technique, these same dose constraints are achievable in 90% of cases, which supports the idea that dose escalation for LAPC is feasible and should be investigated in clinical trials. Our data provide a roadmap for other clinicians looking to achieve dose escalation up to 60Gy in 5 fractions for pancreatic cancer in the appropriate setting.</p></sec></body><back><ref-list hwp:id="ref-list-1"><title hwp:id="title-17">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Von Hoff DD"><surname>Von Hoff</surname> <given-names>DD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ervin T"><surname>Ervin</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Arena FP"><surname>Arena</surname> <given-names>FP</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-2">Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</article-title>. <source hwp:id="source-1">N Engl J Med</source> <year>2013</year>;<volume>369</volume>:<fpage>1691</fpage>–<lpage>703</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Conroy T"><surname>Conroy</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Desseigne F"><surname>Desseigne</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ychou M"><surname>Ychou</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-3">FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source hwp:id="source-2">N Engl J Med</source> <year>2011</year>;<volume>364</volume>:<fpage>1817</fpage>–<lpage>25</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Hammel P"><surname>Hammel</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Huguet F"><surname>Huguet</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="van Laethem JL"><surname>van Laethem</surname> <given-names>JL</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-4">Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial</article-title>. <source hwp:id="source-3">JAMA</source> <year>2016</year>;<volume>315</volume>:<fpage>1844</fpage>–<lpage>53</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Krishnan S"><surname>Krishnan</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chadha AS"><surname>Chadha</surname> <given-names>AS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Suh Y"><surname>Suh</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-5">Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation</article-title>. <source hwp:id="source-4">Int J Radiat Oncol Biol Phys</source> <year>2016</year>;<volume>94</volume>:<fpage>755</fpage>–<lpage>65</lpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Colbert LE"><surname>Colbert</surname> <given-names>LE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Moningi S"><surname>Moningi</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chadha A"><surname>Chadha</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-6">Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC</article-title>. <source hwp:id="source-5">Adv Radiat Oncol</source> <year>2017</year>;<volume>2</volume>:<fpage>403</fpage>–<lpage>15</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Isaji S"><surname>Isaji</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mizuno S"><surname>Mizuno</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Windsor JA"><surname>Windsor</surname> <given-names>JA</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-7">International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017</article-title>. <source hwp:id="source-6">Pancreatology</source> <year>2018</year>;<volume>18</volume>:<fpage>2</fpage>–<lpage>11</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Colbert LE"><surname>Colbert</surname> <given-names>LE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fisher SB"><surname>Fisher</surname> <given-names>SB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Balci S"><surname>Balci</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-8">High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma</article-title>. <source hwp:id="source-7">Int J Radiat Oncol Biol Phys</source> <year>2015</year>;<volume>91</volume>:<fpage>631</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Yaparpalvi R"><surname>Yaparpalvi</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Garg MK"><surname>Garg</surname> <given-names>MK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shen J"><surname>Shen</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-9">Evaluating which plan quality metrics are appropriate for use in lung SBRT</article-title>. <source hwp:id="source-8">Br J Radiol</source> <year>2018</year>;<volume>91</volume>:<fpage>20170393</fpage>.</citation></ref><ref id="c9" hwp:id="ref-9"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Comito T"><surname>Comito</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cozzi L"><surname>Cozzi</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zerbi A"><surname>Zerbi</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-10">Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study</article-title>. <source hwp:id="source-9">Eur J Surg Oncol</source> <year>2017</year>;<volume>43</volume>:<fpage>735</fpage>–<lpage>42</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Chang DT"><surname>Chang</surname> <given-names>DT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schellenberg D"><surname>Schellenberg</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shen J"><surname>Shen</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-11">Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas</article-title>. <source hwp:id="source-10">Cancer</source> <year>2009</year>;<volume>115</volume>:<fpage>665</fpage>–<lpage>72</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Barney BM"><surname>Barney</surname> <given-names>BM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Olivier KR"><surname>Olivier</surname> <given-names>KR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Macdonald OK"><surname>Macdonald</surname> <given-names>OK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fong de Los Santos LE"><surname>Fong de Los Santos</surname> <given-names>LE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Miller RC"><surname>Miller</surname> <given-names>RC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Haddock MG"><surname>Haddock</surname> <given-names>MG</given-names></string-name>. <article-title hwp:id="article-title-12">Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors</article-title>. <source hwp:id="source-11">Am J Clin Oncol</source> <year>2012</year>;<volume>35</volume>:<fpage>537</fpage>–<lpage>42</lpage>.</citation></ref><ref id="c12" hwp:id="ref-12"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Chuong MD"><surname>Chuong</surname> <given-names>MD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Springett GM"><surname>Springett</surname> <given-names>GM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Freilich JM"><surname>Freilich</surname> <given-names>JM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-13">Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated</article-title>. <source hwp:id="source-12">Int J Radiat Oncol Biol Phys</source> <year>2013</year>;<volume>86</volume>:<fpage>516</fpage>–<lpage>22</lpage>.</citation></ref><ref id="c13" hwp:id="ref-13"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Herman JM"><surname>Herman</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chang DT"><surname>Chang</surname> <given-names>DT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Goodman KA"><surname>Goodman</surname> <given-names>KA</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-14">Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma</article-title>. <source hwp:id="source-13">Cancer</source> <year>2015</year>;<volume>121</volume>:<fpage>1128</fpage>–<lpage>37</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Navarria P"><surname>Navarria</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ascolese AM"><surname>Ascolese</surname> <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mancosu P"><surname>Mancosu</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-15">Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC)</article-title>. <source hwp:id="source-14">Radiother Oncol</source> <year>2013</year>;<volume>107</volume>:<fpage>414</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Gurka MK"><surname>Gurka</surname> <given-names>MK</given-names></string-name>, <string-name name-style="western" hwp:sortable="Collins SP"><surname>Collins</surname> <given-names>SP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Slack R"><surname>Slack</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-16">Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety</article-title>. <source hwp:id="source-15">Radiat Oncol</source> <year>2013</year>;<volume>8</volume>:<fpage>44</fpage>.</citation></ref><ref id="c16" hwp:id="ref-16"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Mellon EA"><surname>Mellon</surname> <given-names>EA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hoffe SE"><surname>Hoffe</surname> <given-names>SE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Springett GM"><surname>Springett</surname> <given-names>GM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-17">Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma</article-title>. <source hwp:id="source-16">Acta Oncol</source> <year>2015</year>;<volume>54</volume>:<fpage>979</fpage>–<lpage>85</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="324129v1.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Shaib WL"><surname>Shaib</surname> <given-names>WL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hawk N"><surname>Hawk</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cassidy RJ"><surname>Cassidy</surname> <given-names>RJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-18">A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (<ext-link l:rel="related" l:ref-type="CLINTRIALGOV" l:ref="NCT01446458" ext-link-type="clintrialgov" xlink:href="NCT01446458" hwp:id="ext-link-3">NCT01446458</ext-link>)</article-title>. <source hwp:id="source-17">Int J Radiat Oncol Biol Phys</source> <year>2016</year>;<volume>96</volume>:<fpage>296</fpage>–<lpage>303</lpage>.</citation></ref></ref-list></back></article>
